Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis.

@article{Menting2014DrugSI,
  title={Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis.},
  author={Stef P Menting and Anand Sitaram and H M Bonnerjee-van der Stok and Menno A. de Rie and Lotty Hooft and P I Spuls},
  journal={The British journal of dermatology},
  year={2014},
  volume={171 4},
  pages={875-83}
}
BACKGROUND Drug survival depends on several factors such as dosing, effectiveness, quality-of-life improvement and safety, and could be seen as an overall marker for treatment success. Such data for biologics in psoriasis treatment are sparse. OBJECTIVES To determine differences in drug survival between different biologics for psoriasis. METHODS Drug survival, dosing, Psoriasis Area and Severity Index (PASI) and Skindex-29 at weeks 12 and 52, and adverse events of patients with psoriasis… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…